Alvotech Secures $165 Million to Fuel Biosimilar Breakthroughs

Reykjavik, Thursday, 18 June 2026.
Alvotech has successfully closed a $165 million capital raise through a public offering and private placement, marking one of the largest funding rounds in biosimilar development this year. The proceeds will accelerate the company’s pipeline of nine biosimilar candidates, targeting high-cost biologics like Humira and Stelara. What makes this raise stand out? It signals strong investor confidence in Alvotech’s ability to disrupt the $300 billion global biologics market with affordable alternatives. With five approved biosimilars already on the market, this funding could position Alvotech as a leader in the next wave of cost-saving therapies.